Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.
暂无分享,去创建一个
S. Rich | R. Barst | A. Frost | R. Naeije | G. Simonneau | A. Keogh | R. Oudiz | L. Rubin | R. Bourge | N. Galiè | J. Crow | S. Blackburn
[1] M. Hoeper,et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. , 2000, The New England journal of medicine.
[2] W. Seeger,et al. Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial , 2000, Annals of Internal Medicine.
[3] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[4] A. Fishman. Epoprostenol (Prostacyclin) and Pulmonary Hypertension , 2000, Annals of Internal Medicine.
[5] M. Fujita,et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.
[6] Y. Okano,et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. , 1999, Journal of the American College of Cardiology.
[7] S. Rich,et al. Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case Series , 1999, Annals of Internal Medicine.
[8] R. Barst,et al. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. , 1999, Circulation.
[9] M. Humbert,et al. Treatment of pulmonary hypertension secondary to connective tissue diseases , 1999, Thorax.
[10] K. Stenmark,et al. Treatments for severe pulmonary hypertension , 1999, The Lancet.
[11] S. Rich,et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. , 1998, The New England journal of medicine.
[12] L. Rubin,et al. Primary pulmonary hypertension. , 1997, The New England journal of medicine.
[13] Y. Okano,et al. Orally active prostacyclin analogue in primary pulmonary hypertension , 1997, The Lancet.
[14] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[15] J. Sailstad,et al. The pharmacokinetics and pharmacodynamics of the prostacyclin analog 15AU81 in the anesthetized beagle dog. , 1993, Prostaglandins, leukotrienes, and essential fatty acids.
[16] D. Graham,et al. Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous catheters. , 1991, The American journal of medicine.
[17] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[18] M. Mata,et al. The effects of 15AU81, a chemically stable prostacyclin analog, on the cardiovascular and renin-angiotensis systems of anesthetized dogs , 1991 .
[19] A. Feinstein,et al. Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. , 1989, The American journal of cardiology.
[20] E H Bergofsky,et al. Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.
[21] T. Rector. Patients' self-assessment of their congestive heart failure : Content, reliability, and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire , 1987 .
[22] G. Guyatt,et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. , 1985, Canadian Medical Association journal.
[23] G. Borg. Psychophysical bases of perceived exertion. , 1982, Medicine and science in sports and exercise.